Maze Therapeutics, Inc. (MAZE) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
MAZE currently has 49.3M outstanding shares. with limited dilution risk as only 8.97M additional shares (18.2%) are authorized for issuance. The company has significantly diluted shareholders by 1798.43% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 12, 2026 |
POS AM filing: This POS AM filing provides for the resale of shares of common stock by Selling Stockholders, including shares issuable upon the exercise of Pre-Funded Warrants. |
49M | 9M |
| May 12, 2026 |
10-Q filing | 53.9M shares outstanding |
54M | 9M |
| Apr 22, 2026 |
8-K filing: Maze Therapeutics, Inc. has priced an offering of 5,540,000 shares of common stock at $23.50 per share and pre-funded warrants to purchase 850,000 shares of common stock at $23.499 per warrant, estimating net proceeds of approximately $144.7 million. |
49M | 9M |
| Mar 25, 2026 |
10-K filing | 49.3M shares outstanding |
49M | 9M |
| Nov 06, 2025 |
10-Q filing | 45.8M shares outstanding |
46M | 9M |
| Oct 17, 2025 |
S-1 filing: This S-1 filing relates to the resale of common stock by selling stockholders. |
44M | 9M |
| Sep 11, 2025 |
8-K filing: Maze Therapeutics, Inc. entered into a securities purchase agreement to sell and issue shares of common stock and pre-funded warrants in a private placement. |
44M | 9M |
| Aug 12, 2025 |
10-Q filing | 43.8M shares outstanding |
44M | 9M |
| May 14, 2025 |
10-Q filing | 43.8M shares outstanding |
44M | 9M |
| Jan 30, 2025 |
S-1/A filing: This S-1/A filing outlines the proposed offering of common stock, with an option for underwriters to purchase additional shares, and details the company's financial status, including historical losses and plans for the use of proceeds from the offering. |
2.4M | 9M |
| Jan 27, 2025 |
S-1/A filing: This is an S-1/A filing for an initial public offering of common stock. |
43M | 8.2M |
| Jan 07, 2025 |
S-1 filing: This is an S-1 filing for an initial public offering of common stock, including an underwriter option, by a clinical-stage biopharmaceutical company. |
24M | 0 |